Drug Approval | February 18, 2022
USFDA accepts Mirati Therapeutics' New Drug Application for Adagrasib
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Virginia will be responsible for meeting client needs for both media and commercial analytics.
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Funding to grow the insurance and digital therapeutics vertical in India
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
The first patient in India treated at Jaslok Hospital and Research Centre, Mumbai Includes the world’s smallest implantable spinal cord stimulator
The Ayurveda storefront will enhance visibility of unique Ayurveda products from Indian small businesses and D2C brands
GOSTAR's proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem's RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
Subscribe To Our Newsletter & Stay Updated
